EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

Given this risk, we thought we'd take a look at whether CRISPR Therapeutics (NASDAQ:CRSP) shareholders should be worried ...

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report).

What exactly drives a company's stock price higher? Intuitively, it's investor demand, but dig deeper — why are investors flocking to buy certain stocks beyond just fear of missing out?

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $48.05, representing a +0.47% change from its previous close.

Let's examine what this company is planning for the future, and figure out whether that makes its stock worth buying or not.

Longer Term Trading Plans for CRSP. Buy CRSP near 40.82 target 52.08 stop loss @ 40.7 Details; The technical summary data ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $45.20, marking a -0.64% move from the previous day. This move lagged the S&P 500's daily gain of 0.97%. Elsewhere, the Dow ...

On Tuesday, TD (TSX:TD) Cowen maintained a Sell rating on CRISPR Therapeutics (NASDAQ:CRSP) shares with a steady price target of $30.00. The firm's analysis adjusted the Q2 ...